| Primary |
| Drug Use For Unknown Indication |
36.5% |
| Postoperative Care |
19.3% |
| Local Anaesthesia |
4.6% |
| Lymphoma |
4.6% |
| Product Used For Unknown Indication |
4.4% |
| Chronic Obstructive Pulmonary Disease |
4.1% |
| Rosacea |
3.6% |
| Uveitis |
2.3% |
| Evans Syndrome |
2.1% |
| Prophylaxis Against Transplant Rejection |
2.1% |
| Systemic Lupus Erythematosus |
2.1% |
| Endophthalmitis |
1.8% |
| Iridocyclitis |
1.8% |
| Rheumatoid Arthritis |
1.8% |
| Ulcerative Keratitis |
1.8% |
| Cataract Operation |
1.5% |
| Immunosuppression |
1.5% |
| Scleritis |
1.5% |
| Diabetes Mellitus |
1.3% |
| Infection Prophylaxis |
1.3% |
|
| Fibrous Histiocytoma |
8.1% |
| Transplant Rejection |
8.1% |
| Intraocular Pressure Increased |
7.0% |
| Ulcerative Keratitis |
7.0% |
| Drug Ineffective |
5.8% |
| Melaena |
5.8% |
| Parophthalmia |
5.8% |
| Visual Acuity Reduced |
5.8% |
| Pregnancy |
4.7% |
| Product Substitution Issue |
4.7% |
| Stillbirth |
4.7% |
| Weight Decreased |
4.7% |
| Acute Generalised Exanthematous Pustulosis |
3.5% |
| Eye Irritation |
3.5% |
| Jaundice |
3.5% |
| Macular Fibrosis |
3.5% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
3.5% |
| Renal Impairment |
3.5% |
| Therapeutic Response Unexpected With Drug Substitution |
3.5% |
| Uveitis |
3.5% |
|
| Secondary |
| Cataract Operation |
35.2% |
| Renal Transplant |
7.6% |
| Product Used For Unknown Indication |
7.0% |
| Postoperative Care |
6.6% |
| Idiopathic Thrombocytopenic Purpura |
5.5% |
| Rheumatoid Arthritis |
4.2% |
| Burkitt's Lymphoma |
3.3% |
| Diffuse Large B-cell Lymphoma |
3.3% |
| Liver Transplant |
3.3% |
| Stem Cell Transplant |
3.3% |
| Prophylaxis |
2.7% |
| Prostate Cancer Metastatic |
2.5% |
| Analgesic Therapy |
2.3% |
| Eye Oedema |
2.3% |
| Preoperative Care |
2.0% |
| Prophylaxis Against Transplant Rejection |
2.0% |
| Glaucoma |
1.8% |
| Hypertension |
1.7% |
| Immunosuppression |
1.7% |
| Mantle Cell Lymphoma |
1.7% |
|
| Toxic Anterior Segment Syndrome |
32.1% |
| White Blood Cell Count Increased |
10.1% |
| Endophthalmitis |
6.4% |
| Graft Versus Host Disease |
4.6% |
| Intraocular Pressure Increased |
4.6% |
| Neutropenia |
3.7% |
| Pleural Effusion |
3.7% |
| Tumour Lysis Syndrome |
3.7% |
| Vision Blurred |
3.7% |
| Vitreous Opacities |
3.7% |
| Eye Pain |
2.8% |
| Off Label Use |
2.8% |
| Pyrexia |
2.8% |
| Retinal Detachment |
2.8% |
| Swelling Face |
2.8% |
| Transplant Rejection |
2.8% |
| Acute Generalised Exanthematous Pustulosis |
1.8% |
| Bacterial Sepsis |
1.8% |
| Corneal Deposits |
1.8% |
| Corneal Infiltrates |
1.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.5% |
| Prophylaxis |
15.1% |
| Aplastic Anaemia |
9.1% |
| Drug Use For Unknown Indication |
7.6% |
| Infection Prophylaxis |
6.8% |
| Hiv Infection |
4.2% |
| Pneumocystis Jiroveci Pneumonia |
3.9% |
| Premedication |
3.8% |
| Hypertension |
3.7% |
| Renal Transplant |
3.4% |
| Rheumatoid Arthritis |
3.2% |
| Bone Marrow Conditioning Regimen |
2.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.3% |
| Constipation |
2.0% |
| Postoperative Care |
2.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.9% |
| Acute Myeloid Leukaemia |
1.8% |
| Pulmonary Tuberculosis |
1.8% |
| Antiviral Prophylaxis |
1.7% |
| Mantle Cell Lymphoma |
1.6% |
|
| White Blood Cell Count Decreased |
10.4% |
| Pneumonia |
8.0% |
| Vomiting |
7.5% |
| Weight Decreased |
6.5% |
| White Blood Cell Count Increased |
6.5% |
| Urinary Tract Infection |
5.5% |
| Visual Acuity Reduced |
5.5% |
| Sepsis |
4.5% |
| Thrombotic Microangiopathy |
4.5% |
| Vision Blurred |
4.5% |
| Wheezing |
4.5% |
| Renal Failure |
4.0% |
| Toxic Anterior Segment Syndrome |
4.0% |
| Uterine Haemorrhage |
4.0% |
| Keratitis |
3.5% |
| Pyrexia |
3.5% |
| Respiratory Failure |
3.5% |
| Therapeutic Response Decreased |
3.5% |
| Throat Tightness |
3.5% |
| Asthenia |
3.0% |
|
| Interacting |
| Thoracic Vertebral Fracture |
57.1% |
| Atrial Fibrillation |
42.9% |
|
|
